<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31708062</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4733</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</Title><ISOAbbreviation>Value Health</ISOAbbreviation></Journal><ArticleTitle>Health Utilities and Costs for Motor Neurone Disease.</ArticleTitle><Pagination><StartPage>1257</StartPage><EndPage>1265</EndPage><MedlinePgn>1257-1265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jval.2019.05.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1098-3015(19)32233-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Motor neurone disease (MND) places a significant burden on patients, their carers, and healthcare systems.</AbstractText><AbstractText Label="OBJECTIVES">To estimate health utilities and costs of MND within the UK setting.</AbstractText><AbstractText Label="METHODS">Patients with MND, recruited via 22 regional clinics, completed a postal questionnaire of a cost and quality-of-life survey. Health outcome assessment included the EuroQoL (EQ)-5D-5L, EQ-5D-visual analogue scale, Amyotrophic Lateral Sclerosis Utility Index, and the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised. Clinical staging was based on the Kings and Milano-Torino (MiToS) systems. The questionnaire asked about patients' use of primary, secondary, and community care services in the previous 3 months. Variability in total costs was examined using regression models.</AbstractText><AbstractText Label="RESULTS">595 patients were included in the health utility analysis, of whom 584 patients also completed a resource use questionnaire. Mean health utility decreased and costs increased between consecutive Kings stages, from 0.76 (95% CI 0.71-0.80) and &#xa3;1096 (&#xa3;757-&#xa3;1240) in Kings stage 1, to 0.50 (0.45-0.54) and &#xa3;3311 (&#xa3;2666-&#xa3;4151) in stage 4, respectively. The changes by MiToS stages were from 0.71 (0.69-0.73) and &#xa3;1115 (&#xa3;937-&#xa3;1130) in MiToS stage 0, to 0.25 (0.07-0.42) and &#xa3;2899 (&#xa3;2190-&#xa3;3840) in stage 2. Kings stages 3 and 4 and MiToS stages 1 and 2, respectively, were significant in explaining variability in total costs.</AbstractText><AbstractText Label="CONCLUSIONS">The impact of MND on health utilities and costs differs by disease severity. The data provided here can be used in cost-effectiveness analyses and to inform decision-making regarding healthcare provision for people with MND.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 ISPOR&#x2013;The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, England, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Carolyn A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>The Walton Centre NHS Trust, Liverpool, England, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Dyfrig A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, England, UK. Electronic address: d.a.hughes@bangor.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>YOUNG/JAN15/929-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Value Health</MedlineTA><NlmUniqueID>100883818</NlmUniqueID><ISSNLinking>1098-3015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006296" MajorTopicYN="N">Health Services</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R</Keyword><Keyword MajorTopicYN="N">EQ-5D</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">costs</Keyword><Keyword MajorTopicYN="N">motor neurone disease</Keyword><Keyword MajorTopicYN="N">utility</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31708062</ArticleId><ArticleId IdType="doi">10.1016/j.jval.2019.05.011</ArticleId><ArticleId IdType="pii">S1098-3015(19)32233-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>